186 related articles for article (PubMed ID: 1355090)
1. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090
[TBL] [Abstract][Full Text] [Related]
2. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
Guy PM; Carraway KL; Cerione RA
J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
[TBL] [Abstract][Full Text] [Related]
3. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene.
Lev S; Yarden Y; Givol D
Mol Cell Biol; 1990 Nov; 10(11):6064-8. PubMed ID: 1700279
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
Peles E; Levy RB; Or E; Ullrich A; Yarden Y
EMBO J; 1991 Aug; 10(8):2077-86. PubMed ID: 1676673
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
6. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
Stern DF; Heffernan PA; Weinberg RA
Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
[TBL] [Abstract][Full Text] [Related]
7. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.
Shu HK; Pelley RJ; Kung HJ
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9103-7. PubMed ID: 1979168
[TBL] [Abstract][Full Text] [Related]
8. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active.
Yarden Y
Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2569-73. PubMed ID: 1969636
[TBL] [Abstract][Full Text] [Related]
9. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
Lehväslaiho H; Lehtola L; Sistonen L; Alitalo K
EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807
[TBL] [Abstract][Full Text] [Related]
10. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation.
Peles E; Lamprecht R; Ben-Levy R; Tzahar E; Yarden Y
J Biol Chem; 1992 Jun; 267(17):12266-74. PubMed ID: 1351056
[TBL] [Abstract][Full Text] [Related]
11. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.
Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ
J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
Stern DF; Kamps MP; Cao H
Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744
[TBL] [Abstract][Full Text] [Related]
13. The effects of the normal and oncogenic forms of the neu tyrosine kinase, and the corresponding forms of an immunoglobulin E receptor/neu tyrosine kinase fusion protein, on Xenopus oocyte maturation.
Narasimhan V; Hamill O; Cerione RA
FEBS Lett; 1992 Jun; 303(2-3):164-8. PubMed ID: 1351469
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of tyrosine kinase activity of the Drosophila epidermal growth factor receptor homolog by alterations of the transmembrane domain.
Wides RJ; Zak NB; Shilo BZ
Eur J Biochem; 1990 May; 189(3):637-45. PubMed ID: 1972062
[TBL] [Abstract][Full Text] [Related]
15. A single amino acid substitution is sufficient to modify the mitogenic properties of the epidermal growth factor receptor to resemble that of gp185erbB-2.
Di Fiore PP; Helin K; Kraus MH; Pierce JH; Artrip J; Segatto O; Bottaro DP
EMBO J; 1992 Nov; 11(11):3927-33. PubMed ID: 1356764
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor (EGF) modulation of feline sarcoma virus fms tyrosine kinase activity, internalization, degradation, and transforming potential in an EGF receptor/v-fms chimera.
Riedel H
J Virol; 1994 Jan; 68(1):411-24. PubMed ID: 8254751
[TBL] [Abstract][Full Text] [Related]
17. A chimeric EGFR/neu receptor in functional analysis of the neu oncoprotein.
Lehtola L; Lehväslaiho H; Koskinen P; Alitalo K
Acta Oncol; 1992; 31(2):147-50. PubMed ID: 1352454
[TBL] [Abstract][Full Text] [Related]
18. A subdomain in the transmembrane domain is necessary for p185neu* activation.
Cao H; Bangalore L; Bormann BJ; Stern DF
EMBO J; 1992 Mar; 11(3):923-32. PubMed ID: 1347745
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells.
Kraus MH; Fedi P; Starks V; Muraro R; Aaronson SA
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2900-4. PubMed ID: 8464905
[TBL] [Abstract][Full Text] [Related]
20. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation.
Samanta A; LeVea CM; Dougall WC; Qian X; Greene MI
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1711-5. PubMed ID: 7907421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
